The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.
 
Thierry Andre
Honoraria - AMGEN; AMGEN; AMGEN; AMGEN; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Xbiotech; Xbiotech; Xbiotech; Xbiotech
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Guardant Health; Guardant Health; Guardant Health; Guardant Health; HalioDX; HalioDX; HalioDX; HalioDX; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; SERVIER; SERVIER; SERVIER; SERVIER; Tesaro; Tesaro; Tesaro; Tesaro
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems
 
Dominique Berton
No Relationships to Disclose
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Dompè; Dompè; Dompè; Dompè; EMD SERONO; EMD SERONO; EMD SERONO; EMD SERONO; Ignyta; Ignyta; Ignyta; Ignyta; Incyte; Incyte; Incyte; Incyte; Novartis; Novartis; Novartis; Novartis; Octimet; Octimet; Octimet; Octimet; Pfizer; Pfizer; Pfizer; Pfizer; Pharm Research associated; Pharm Research associated; Pharm Research associated; Pharm Research associated; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Teofarma; Teofarma; Teofarma; Teofarma
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Menarini; Menarini; Menarini; Menarini; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma; Ellipses Pharma; Ellipses Pharma; Ellipses Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Samsung; Samsung; Samsung; Samsung
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Samsung; Samsung; Samsung; Samsung
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
 
Wei Guo
Employment - Tesaro; Tesaro; Tesaro; Tesaro
 
Hadi Danaee
Employment - Tesaro; Tesaro; Tesaro; Tesaro
 
Sharon Lu
Employment - Tesaro; Tesaro; Tesaro; Tesaro
 
Ellie Im
Employment - Tesaro; Tesaro; Tesaro; Tesaro
 
Naureen Starling
Honoraria - Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology